| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3996 | 2015 |
| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2409 | 2015 |
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1792 | 2018 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 635 | 2020 |
| Plasma AR and abiraterone-resistant prostate cancer A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... Science translational medicine 7 (312), 312re10-312re10, 2015 | 482 | 2015 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 418 | 2017 |
| Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European urology 76 (4), 469-478, 2019 | 405 | 2019 |
| Tumor clone dynamics in lethal prostate cancer S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ... Science translational medicine 6 (254), 254ra125-254ra125, 2014 | 399 | 2014 |
| METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based … AR Padhani, FE Lecouvet, N Tunariu, DM Koh, F De Keyzer, DJ Collins, ... European urology 71 (1), 81-92, 2017 | 327 | 2017 |
| PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 290 | 2015 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 276 | 2020 |
| Visceral disease in castration-resistant prostate cancer CJ Pezaro, A Omlin, D Lorente, DN Rodrigues, R Ferraldeschi, ... European urology 65 (2), 270-273, 2014 | 255 | 2014 |
| Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial KH Khan, D Cunningham, B Werner, G Vlachogiannis, I Spiteri, T Heide, ... Cancer discovery 8 (10), 1270-1285, 2018 | 237 | 2018 |
| Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies TA Yap, D Olmos, AT Brunetto, N Tunariu, J Barriuso, R Riisnaes, L Pope, ... Journal of Clinical Oncology 29 (10), 1271-1279, 2011 | 227 | 2011 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195-3204, 2020 | 216 | 2020 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 214 | 2015 |
| The Lancet Commission on prostate cancer: planning for the surge in cases ND James, I Tannock, J N'Dow, F Feng, S Gillessen, SA Ali, B Trujillo, ... The Lancet 403 (10437), 1683-1722, 2024 | 194 | 2024 |
| Targeting the p300/CBP axis in lethal prostate cancer J Welti, A Sharp, N Brooks, W Yuan, C McNair, SN Chand, A Pal, ... Cancer Discovery 11 (5), 1118-1137, 2021 | 192 | 2021 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 152 | 2018 |
| Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a … MD Blackledge, DJ Collins, N Tunariu, MR Orton, AR Padhani, MO Leach, ... PloS one 9 (4), e91779, 2014 | 149 | 2014 |
